The Latest in Critical Care, 10/23/23 (Issue #17)

ACORN trial (cefepime vs. pip-tazo), Paxlovid for Omicron, MDROs on the rise

Oct 23, 2023

∙ Paid

Piperacillin-Tazobactam vs. Cefepime for Kidney Injury and Neurologic Dysfunction (ACORN Trial)

Piperacillin-tazobactam, marketed as Zosyn, has been one of the most-prescribed broad spectrum antibiotics for many years, used for its bactericidal activity against most gram-negative and anaerobic bacteria, including Pseudomonas. Cefepime has similar antibac…

Keep reading with a 7-day free trial

Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.